GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerative Medical Technology Group Inc (OTCPK:RMTG) » Definitions » Debt-to-Revenue

RMTG (Regenerative Medical Technology Group) Debt-to-Revenue : 5.04 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Regenerative Medical Technology Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Regenerative Medical Technology Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $17.41 Mil. Regenerative Medical Technology Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.45 Mil. Regenerative Medical Technology Group's annualized Revenue for the quarter that ended in Sep. 2024 was $3.94 Mil. Regenerative Medical Technology Group's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 5.04.


Regenerative Medical Technology Group Debt-to-Revenue Historical Data

The historical data trend for Regenerative Medical Technology Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerative Medical Technology Group Debt-to-Revenue Chart

Regenerative Medical Technology Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 53.57 105.07 31.11 9.90 7.32

Regenerative Medical Technology Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.72 7.16 5.75 6.25 5.04

Competitive Comparison of Regenerative Medical Technology Group's Debt-to-Revenue

For the Biotechnology subindustry, Regenerative Medical Technology Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerative Medical Technology Group's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerative Medical Technology Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Regenerative Medical Technology Group's Debt-to-Revenue falls into.


;
;

Regenerative Medical Technology Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Regenerative Medical Technology Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(15.226 + 2.425) / 2.41
=7.32

Regenerative Medical Technology Group's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(17.408 + 2.452) / 3.944
=5.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Regenerative Medical Technology Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Regenerative Medical Technology Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerative Medical Technology Group Business Description

Traded in Other Exchanges
N/A
Address
433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc operates through its subsidiary. Its focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. It believes stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. Patients around the world are seeking a natural regenerative alternative without the potential risks and side effects sometimes associated with conventional pharmaceuticals.
Executives
Benito Novas 10 percent owner 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
David Eugene Christensen director, 10 percent owner, officer: President and CEO 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Pereira Melvin Antonio Loria director, 10 percent owner, officer: CEO, Chairman RESIDENCIAL HACIENDA EL GREGAL, #24-1 SANCHEZ, CURRIDABAT, SAN JOSE G2 11803